Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has 11 years of Non-Current Deffered Revenue data on file, last reported at $175000.0 in Q3 2023.

• Non-Current Deffered Revenue for Q3 2023 came in at $175000.0, down 12.06% year-over-year; the trailing twelve-month figure through Sep 2023 was $175000.0 (down 12.06% YoY), and the FY2022 annual result was $192000.0, down 38.06% from the prior year.
• Non-Current Deffered Revenue fell to $175000.0 in Q3 2023 per TBPH's latest filing, from $181000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $21.7 million in Q1 2019 and troughed at $175000.0 in Q3 2023.
• A 5-year average of $3.7 million and a median of $329000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2019 and 2021: Non-Current Deffered Revenue jumped 276.52% in 2019, then tumbled 96.02% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $6.8 million in 2019, then plunged by 94.85% to $348000.0 in 2020, then dropped by 10.92% to $310000.0 in 2021, then sank by 38.06% to $192000.0 in 2022, then slipped by 8.85% to $175000.0 in 2023.
• Business Quant data shows TBPH's Non-Current Deffered Revenue at $175000.0 in Q3 2023, $181000.0 in Q2 2023, and $187000.0 in Q1 2023.